TCG Crossover Management, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), TCG Crossover Management, LLC reported 32 stock positions worth $959.5 million. Its top holding was CG Oncology (CGON) at 12.1% of the portfolio, followed by Dyne Therapeutics (DYN, 9.7%) and Abivax SA-ADR (ABVX, 8.3%). Compared with Q1 2024, it opened 2 new positions, sold out of 3, added to 6 and reduced 4. The biggest buy was Abivax SA-ADR (ABVX, shares +451%) and the biggest sale an exit from Inhibrx.
- Most Recent 13F
- Q2 2026
- Location
- PALO ALTO, CA
- CIK
- 0001839948
- Portfolio Value
- $959.5M (Q2 2024)
- SEC Filing
- 0001214659-24-014472 ↗ filed Aug 14, 2024
Holdings Value
Holdings 32 stocks · $959.5M
| CGON CG Oncology Inc. | 12.08% | 3,670,206 | $115.9M | Add +2.8% |
| DYN Dyne Therapeutics Inc. | 9.75% | 2,650,150 | $93.5M | No change |
| ABVX Abivax SA-ADR | 8.34% | 6,056,596 | $80.1M | Add +450.6% |
| SLN Silence Therapeutics PLC-ADR | 6.53% | 3,295,350 | $62.6M | No change |
| COGT Cogent Biosciences Inc. | 6.12% | 6,964,375 | $58.7M | Add +12.1% |
| SVRA Savara Inc. | 5.19% | 12,362,205 | $49.8M | Add +23.6% |
| MDGL Madrigal Pharmaceuticals Inc. | 4.36% | 149,283 | $41.8M | No change |
| EWTX Edgewise Therapeutics Inc. | 4.27% | 2,272,728 | $40.9M | No change |
| KROS Keros Therapeutics Inc. | 4.19% | 879,344 | $40.2M | No change |
| MLYS Mineralys Therapeutics Inc. | 3.88% | 3,185,185 | $37.3M | No change |
| OCUL Ocular Therapeutix Inc. | 3.79% | 5,319,148 | $36.4M | No change |
| TYRA Tyra Biosciences Inc. | 3.31% | 1,989,103 | $31.8M | No change |
| KURA Kura Oncology Inc. | 3.06% | 1,423,642 | $29.3M | No change |
| GPCR Structure Therapeutics Inc. | 2.84% | 694,547 | $27.3M | Reduce -56.5% |
| CNTA Centessa Pharmaceuticals Ltd. | 2.72% | 2,890,816 | $26.1M | Add +41.6% |
| ATXS Astria Therapeutics Inc. | 2.62% | 2,761,861 | $25.1M | Reduce -47.7% |
| CMPS Compass Pathways PLC | 2.43% | 3,858,000 | $23.3M | No change |
| SLNO Soleno Therapeutics Inc. | 2.34% | 550,000 | $22.4M | No change |
| IRON Disc Medicine Inc. | 2.29% | 486,957 | $21.9M | New |
| TRML Tourmaline Bio Inc. | 1.98% | 1,477,593 | $19.0M | No change |
| TARS Tarsus Pharmaceuticals Inc. | 1.58% | 556,317 | $15.1M | Reduce -29.9% |
| ADVM Adverum Biotechnologies Inc. | 1.44% | 2,008,340 | $13.8M | No change |
| VTGN Vistagen Therapeutics Inc. | 0.97% | 2,676,580 | $9.3M | No change |
| TRDA Entrada Therapeutics Inc. | 0.87% | 584,955 | $8.3M | No change |
| EYPT Eyepoint Inc. | 0.84% | 922,335 | $8.0M | New |
| CCCC C4 Therapeutics Inc. | 0.61% | 1,276,574 | $5.9M | No change |
| NKTR Nektar Therapeutics | 0.52% | 4,000,000 | $5.0M | No change |
| AEROVATE THERAPEUTICS INC | 0.39% | 2,240,809 | $3.7M | Add +1.8% |
| ANTX AN2 Therapeutics Inc. | 0.35% | 1,555,118 | $3.3M | No change |
| KOD Kodiak Sciences Inc. | 0.22% | 899,999 | $2.1M | No change |
| VTYX Ventyx Biosciences Inc. | 0.08% | 316,195 | $730K | Reduce -61.2% |
| CABA Cabaletta Bio Inc. | 0.07% | 86,795 | $649K | No change |
Portfolio Sells Q1 2024 → Q2 2024
| INHIBRX INC | Sold out | 0.00% | −4.84 |
| GERN Geron Corp. | Sold out | 0.00% | −4.54 |
| ATXS Astria Therapeutics Inc. | Reduce -47.7% | 2.62% | −3.25 |
| GPCR Structure Therapeutics Inc. | Reduce -56.5% | 2.84% | −2.57 |
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −1.09 |
| TARS Tarsus Pharmaceuticals Inc. | Reduce -29.9% | 1.58% | −0.71 |
| VTYX Ventyx Biosciences Inc. | Reduce -61.2% | 0.08% | −0.28 |
Portfolio Buys Q1 2024 → Q2 2024
| ABVX Abivax SA-ADR | Add +450.6% | 8.34% | +7.10 |
| COGT Cogent Biosciences Inc. | Add +12.1% | 6.12% | +2.82 |
| IRON Disc Medicine Inc. | New | 2.29% | +2.29 |
| SVRA Savara Inc. | Add +23.6% | 5.19% | +1.26 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +41.6% | 2.72% | +0.90 |
| EYPT Eyepoint Inc. | New | 0.84% | +0.84 |
| CGON CG Oncology Inc. | Add +2.8% | 12.08% | −0.32 |
| AEROVATE THERAPEUTICS INC | Add +1.8% | 0.39% | −4.76 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 54 | $4.2B | ABVX, TNGX, CGON, COGT, IMVT |
| Q1 2026 | 49 | $3.5B | ABVX, CGON, TNGX, COGT, CNTA |
| Q4 2025 | 43 | $3.0B | ABVX, COGT, CGON, TNGX, CNTA |
| Q3 2025 | 40 | $2.0B | ABVX, CGON, COGT, AMLX, CNTA |
| Q2 2025 | 37 | $875.5M | CGON, TNGX, COGT, OCUL, CDTX |
| Q1 2025 | 37 | $733.1M | CGON, COGT, CNTA, MLYS, OCUL |
| Q4 2024 | 38 | $1.0B | CGON, DYN, XNCR, COGT, CNTA |
| Q3 2024 | 36 | $1.2B | CGON, DYN, COGT, ABVX, EWTX |
| Q2 2024 | 32 | $959.5M | CGON, DYN, ABVX, SLN, COGT |
| Q1 2024 | 33 | $1.3B | CGON, DYN, ATXS, SLN, GPCR |